Simone Treiger Sredni1,2,3, Chiang-Ching Huang4, Mario Suzuki5,6, Tatiana Pundy5, Pauline Chou7,8, Tadanori Tomita5,9. 1. Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Neurosurgery, Hospital of Chicago, 225 E Chicago Ave., Chicago, IL, 60611, USA. ssredni@luriechildrens.org. 2. Feinberg School of Medicine, Department of Surgery, Northwestern University, 303 E Chicago Ave, Chicago, IL, 60611, USA. ssredni@luriechildrens.org. 3. Cancer Biology and Epigenomics, Stanley Manne Children's Research Institute, 2430 North Halsted St., Chicago, IL, 60614, USA. ssredni@luriechildrens.org. 4. Joseph J. Zilber School of Public Health, University of Wisconsin, 1240 N 10th St, Milwaukee, WI, 53205, USA. 5. Ann and Robert H. Lurie Children's Hospital of Chicago, Division of Pediatric Neurosurgery, Hospital of Chicago, 225 E Chicago Ave., Chicago, IL, 60611, USA. 6. Department of Neurosurgery, Juntendo University, School of Medicine, Hongo, 2-1-1 Bunkyo-ku, Tokyo, 113-8421, Japan. 7. Ann and Robert H. Lurie Children's Hospital of Chicago, Department of Pathology and Laboratory Medicine, Hospital of Chicago, 225 E Chicago Ave., Chicago, IL, 60611, USA. 8. Feinberg School of Medicine, Department of Pediatrics, Northwestern University, 303 E Chicago Ave, Chicago, IL, 60611, USA. 9. Feinberg School of Medicine, Department of Surgery, Northwestern University, 303 E Chicago Ave, Chicago, IL, 60611, USA.
Abstract
BACKGROUND: Pediatric low-grade gliomas (P-LGG) consist of a mixed group of brain tumors that correspond to the majority of CNS tumors in children. Notably, they may exhibit spontaneous involution after subtotal surgical removal (STR). In this study, we investigated molecular indicators of spontaneous involution in P-LGG. METHODS: We performed an integrated molecular analysis including high throughput gene expression (GE), microRNA (miRNA) expression data of primary, untreated tumors from patients with P-LGG who underwent STR at our institution, with at least 10 years follow-up. RESULTS: We identified a set of protein-coding genes and miRNAs significantly differentially expressed in P-LGG that presented spontaneous involution (involution-I) or without progression (stable-S) after STR alone. The cannabinoid receptor 1 (CNR1 or CB1) gene (FC = 2.374; p value = 0.007) was at the top of the list and predicted to be regulated by hsa-miR-29b-3p (FC = -2.353, p value = 0.0001). CNR1 also showed a trend to be higher expressed in S/I by immunohistochemistry. CONCLUSIONS: The P-LGG, which remained stable or that presented spontaneous involution after STR, showed significantly higher CNR1 expression at the time of diagnosis. We hypothesize that high expression levels of CNR1 provide tumor susceptibility to the antitumor effects of circulating endocannabinoids like anandamide, resulting in tumor involution. This corroborates with reports suggesting that CNR1 agonists and activators of the endocannabinoid system may represent therapeutic opportunities for children with LGG. We also suggest that CNR1 may be a prognostic marker for P-LGG. This is the first time spontaneous involution of P-LGG has been suggested to be induced by endocannabinoids.
BACKGROUND: Pediatric low-grade gliomas (P-LGG) consist of a mixed group of brain tumors that correspond to the majority of CNS tumors in children. Notably, they may exhibit spontaneous involution after subtotal surgical removal (STR). In this study, we investigated molecular indicators of spontaneous involution in P-LGG. METHODS: We performed an integrated molecular analysis including high throughput gene expression (GE), microRNA (miRNA) expression data of primary, untreated tumors from patients with P-LGG who underwent STR at our institution, with at least 10 years follow-up. RESULTS: We identified a set of protein-coding genes and miRNAs significantly differentially expressed in P-LGG that presented spontaneous involution (involution-I) or without progression (stable-S) after STR alone. The cannabinoid receptor 1 (CNR1 or CB1) gene (FC = 2.374; p value = 0.007) was at the top of the list and predicted to be regulated by hsa-miR-29b-3p (FC = -2.353, p value = 0.0001). CNR1 also showed a trend to be higher expressed in S/I by immunohistochemistry. CONCLUSIONS: The P-LGG, which remained stable or that presented spontaneous involution after STR, showed significantly higher CNR1 expression at the time of diagnosis. We hypothesize that high expression levels of CNR1 provide tumor susceptibility to the antitumor effects of circulating endocannabinoids like anandamide, resulting in tumor involution. This corroborates with reports suggesting that CNR1 agonists and activators of the endocannabinoid system may represent therapeutic opportunities for children with LGG. We also suggest that CNR1 may be a prognostic marker for P-LGG. This is the first time spontaneous involution of P-LGG has been suggested to be induced by endocannabinoids.
Authors: Jeffrey H Wisoff; Robert A Sanford; Linda A Heier; Richard Sposto; Peter C Burger; Allan J Yates; Emiko J Holmes; Larry E Kun Journal: Neurosurgery Date: 2011-06 Impact factor: 4.654
Authors: Stephan von Hornstein; Rolf-D Kortmann; Torsten Pietsch; Angela Emser; Monika Warmuth-Metz; Niels Soerensen; Ronald Straeter; Norbert Graf; Barbara Thieme; Astrid K Gnekow Journal: Pediatr Blood Cancer Date: 2011-02-11 Impact factor: 3.167
Authors: Katrin Scheinemann; Ute Bartels; Elena Tsangaris; Cynthia Hawkins; Annie Huang; Peter Dirks; Iris Fried; Eric Bouffet; Uri Tabori Journal: Pediatr Blood Cancer Date: 2010-12-01 Impact factor: 3.167
Authors: Cristina Blázquez; María Salazar; Arkaitz Carracedo; Mar Lorente; Ainara Egia; Luis González-Feria; Amador Haro; Guillermo Velasco; Manuel Guzmán Journal: Cancer Res Date: 2008-03-15 Impact factor: 12.701
Authors: Daniel K Nomura; Jonathan Z Long; Sherry Niessen; Heather S Hoover; Shu-Wing Ng; Benjamin F Cravatt Journal: Cell Date: 2010-01-08 Impact factor: 41.582
Authors: Giuseppina Catanzaro; Zein Mersini Besharat; Andrea Carai; Natalie Jäger; Elena Splendiani; Carole Colin; Agnese Po; Martina Chiacchiarini; Anna Citarella; Francesca Gianno; Antonella Cacchione; Evelina Miele; Francesca Diomedi Camassei; Marco Gessi; Luca Massimi; Franco Locatelli; David T W Jones; Dominique Figarella-Branger; Stefan M Pfister; Angela Mastronuzzi; Felice Giangaspero; Elisabetta Ferretti Journal: Biomark Res Date: 2022-06-17
Authors: Alexandru A Sabo; Maria Dudau; George L Constantin; Tudor C Pop; Christoph-M Geilfus; Alessio Naccarati; Mihnea P Dragomir Journal: Front Pharmacol Date: 2021-07-06 Impact factor: 5.810